gyki 52466 has been researched along with Anterior Choroidal Artery Infarction in 2 studies
GYKI 52466: an AMPA (non-NMDA) receptor antagonist; structure given in first source
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buchan, AM | 2 |
| Lesiuk, H | 1 |
| Barnes, KA | 1 |
| Li, H | 1 |
| Huang, ZG | 2 |
| Smith, KE | 2 |
| Xue, D | 2 |
| Barnes, K | 1 |
| Lesiuk, HJ | 1 |
2 other studies available for gyki 52466 and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists?
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Agents; Benzodiazepi | 1993 |
Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Agents; Benzodiazepi | 1994 |